Loomis, Sayles & Company
MNTA

Loomis, Sayles & Company’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Loomis, Sayles & Company’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,163,478
Closed -$38.7M – 747
2020
Q2 		$38.7M Buy
1,163,478
+235,063
+25% +$7.48M 0.06% 119
2020
Q1 		$25.3M Buy
+928,415
New +$25.8M 0.05% 137

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Loomis, Sayles & Company's MNTA Position: Q3 2020 in Review

Loomis, Sayles & Company sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2020, closing a stake of 1,163,478 shares — an estimated $38.7M sold.

Loomis, Sayles & Company first reported a position in MNTA in Q1 2020 and held it in 2 quarters. The position peaked at $38.7M in Q2 2020. 211 funds tracked by Wall St. Rank hold MNTA as of Q3 2020.

  • Loomis, Sayles & Company reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Loomis, Sayles & Company sold 1,163,478 Momenta Pharmaceuticals, Inc. shares in Q3 2020, an estimated $38.7M.
  • Loomis, Sayles & Company first reported a position in Momenta Pharmaceuticals, Inc. in Q1 2020 and held it in 2 quarters.
  • Loomis, Sayles & Company's Momenta Pharmaceuticals, Inc. position peaked at $38.7M in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2020.

Based on Loomis, Sayles & Company's 13F filing for Q3 2020, filed 12 Nov 2020.